AXSM Stock Analysis: Axsome Therapeutics | NASDAQ

Depression Treatment, Sleep Disorder Therapy, Migraine Medication, CNS Therapeutics

Total Rating 36

Safety 29

Buy Signal -0.38

Biotechnology
Industry Rotation: -19.2

Market Cap: 11.3B
Avg Turnover: 158M

Risk 3d forecast

Volatility47.3%

VaR 5^th Pctl7.49%

VaR vs Median-3.88%

Reward TTM

Sharpe Ratio1.77

Rel. Str. IBD82.9

Rel. Str. Peer Group65.2

Character TTM

Beta0.226

Beta Downside-0.048

Hurst Exponent0.402

Drawdowns 3y

Max DD32.69%

CAGR/Max DD1.39

CAGR/Mean DD3.83

EPS (Earnings per Share)

Last SUE: 0.00
Qual. Beats: 0

Revenue

Rev. CAGR: 59.60%
Rev. Trend: 99.4%

Last SUE: -0.79
Qual. Beats: 0

Warnings

Interest Coverage Ratio Critical

Altman Z'' In Financial Distress Zone

Below Avwap Earnings

Tailwinds

No distinct edge detected

Seasonality 10.7 years of data

Jan -8.4% 12

Feb -4.9% 27

Mar -6.8% 28

Apr +13.1% 25

May +0.2% 2

Jun +3.7% 0

Jul -5.3% 25

Aug +1.1% 21

Sep -0.3% 8

Oct +0.2% 8

Nov +10.6% 31

Dec +7.2% 41

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: AXSM Axsome Therapeutics

Axsome Therapeutics is a U.S.-based biopharmaceutical company that develops therapies for central nervous system (CNS) disorders. The company is headquartered in New York and trades on NASDAQ under the ticker AXSM within the GICS Health Care sector, specifically the Pharmaceuticals sub-industry. As a biopharma company, Axsome relies on a pipeline-driven business model in which long development cycles and regulatory approvals are central to revenue generation.

The companys commercial portfolio includes three products: Auvelity (dextromethorphan-bupropion) for major depressive disorder, Sunosi (solriamfetol) for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea, and Symbravo (MoSEIC meloxicam-rizatriptan) for the acute treatment of migraine with or without aura.

Axsomes development pipeline covers several indications within CNS, including AXS-05 for Alzheimers disease agitation and smoking cessation (in collaboration with Duke University), AXS-12 for narcolepsy, AXS-14 for fibromyalgia, and additional studies of solriamfetol across ADHD, major depressive disorder, binge eating disorder, and shift work disorder.

The company was incorporated in 2012 and is based in New York, New York. Like most clinical-stage and commercial-stage pharmaceutical companies, Axsomes value is closely tied to its intellectual property, regulatory milestones, and the outcome of clinical trials across multiple indications.

Headlines to Watch Out For

Auvelity prescription demand accelerates major depressive disorder revenue growth
Symbravo launch targets acute migraine treatment market expansion
AXS-05 Alzheimers agitation Phase 3 readout near-term stock catalyst

Piotroski VR-10 (Strict) 3.0

Net Income: -191.6m TTM > 0 and > 6% of Revenue
FCF/TA: -0.09 > 0.02 and ΔFCF/TA 9.52 > 1.0
NWC/Revenue: 25.26% < 20% (prev 39.29%; Δ -14.04% < -1%)
CFO/TA -0.09 > 3% & CFO -71.3m > Net Income -191.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.43 > 1.5 & < 3
Outstanding Shares: last quarter (51.5m) vs 12m ago 4.16% < -2%
Gross Margin: 93.24% > 18% (prev 91.48%; Δ 1.76% > 0.5%)
Asset Turnover: 110.8% > 50% (prev 77.37%; Δ 33.47% > 0%)
Interest Coverage Ratio: -37.58 > 6 (EBIT TTM -188.5m / Interest Expense TTM 5.02m)

Altman Z'' -6.08

A: 0.26 (Total Current Assets 656.6m - Total Current Liabilities 460.4m) / Total Assets 761.4m
B: -1.87 (Retained Earnings -1.42b / Total Assets 761.4m)
C: -0.27 (EBIT TTM -188.5m / Avg Total Assets 700.6m)
D: 0.12 (Book Value of Equity 83.3m / Total Liabilities 678.1m)
Altman-Z'' = -6.08 = D

Beneish M -2.81

DSRI: 0.89 (Receivables 277.5m/198.8m, Revenue 776.6m/495.0m)
GMI: 0.98 (GM 91.48% / 93.24%)
AQI: 0.89 (AQ_t 0.11 / AQ_t-1 0.13)
SGI: 1.57 (Revenue 776.6m / 495.0m)
TATA: -0.16 (NI -191.6m - CFO -71.3m) / TA 761.4m)
Beneish M = -2.81 (Cap -4..+1) = A

What is the price of AXSM shares?

As of August 14, 2026, the stock is trading at USD 214.66 with a total of 1,236,633 shares traded. Over the past week, the price has changed by +0.85%, over one month by -5.97%, over three months by -4.18% and over the past year by +103.99%.

Current recommended Stop Loss: 203.40 (which is 5.2% or 1.2 ATR below the current price).

Is AXSM a buy, sell or hold?

Axsome Therapeutics has received a consensus analysts rating of 4.74. Therefore, it is recommended to buy AXSM.

StrongBuy: 14
Buy: 5
Hold: 0
Sell: 0
StrongSell: 0

What are the forecasts/targets for the AXSM price?

Analysts Target Price	283.9	32.3%

Axsome Therapeutics (AXSM) - Fundamental Data Overview as of 13 August 2026

Market Cap USD = 11.3b (11.3b USD * 1.0 USD.USD)
P/E Forward = 333.3333
P/S = 14.554
P/B = 208.2354
Revenue TTM = 776.6m USD
EBIT TTM = -188.5m USD
EBITDA TTM = -179.5m USD
Long Term Debt = 117.7m USD (from longTermDebt, last fiscal year)
Short Term Debt = 70.6m USD (from shortTermDebt, last quarter)
Debt = 251.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 32.0m
Net Debt = -68.6m USD (calculated: Debt 251.3m - CCE 319.9m)
Enterprise Value = 11.2b USD (11.3b + Debt 251.3m - CCE 319.9m)
Interest Coverage Ratio = -37.58 (Ebit TTM -188.5m / Interest Expense TTM 5.02m)
EV/FCF = -157.4x (Enterprise Value 11.2b / FCF TTM -71.4m)
FCF Yield = -0.64% (FCF TTM -71.4m / Enterprise Value 11.2b)
FCF Margin = -9.19% (FCF TTM -71.4m / Revenue TTM 776.6m)
Net Margin = -24.68% (Net Income TTM -191.6m / Revenue TTM 776.6m)
Gross Margin = 93.24% ((Revenue TTM 776.6m - Cost of Revenue TTM 52.5m) / Revenue TTM)
Gross Margin QoQ = 93.79% (prev 92.30%)
Tobins Q-Ratio = 14.75 (Enterprise Value 11.2b / Total Assets 761.4m)
Interest Expense / Debt = 2.00% (Interest Expense 5.02m / Debt 251.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -148.9m (EBIT -188.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.43 (Total Current Assets 656.6m / Total Current Liabilities 460.4m)
Debt / Equity = 3.02 (Debt 251.3m / totalStockholderEquity, last quarter 83.3m)
Debt / EBITDA = 0.38 (negative EBITDA) (Net Debt -68.6m / EBITDA -179.5m)
Debt / FCF = 0.96 (negative FCF - burning cash) (Net Debt -68.6m / FCF TTM -71.4m)
Total Stockholder Equity = 75.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -27.35% (Net Income -191.6m / Total Assets 761.4m)
RoE = -255.6% (Net Income TTM -191.6m / Total Stockholder Equity 75.0m)
RoCE = -97.83% (EBIT -188.5m / Capital Employed (Equity 75.0m + L.T.Debt 117.7m))
RoIC = -44.75% (negative operating profit) (NOPAT -148.9m / Invested Capital 332.8m)
WACC = 6.67% (E(11.3b)/V(11.6b) * Re(6.78%) + D(251.3m)/V(11.6b) * Rd(2.00%) * (1-Tc(0.21)))
Discount Rate = 6.78% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 99.56 | Cagr: 3.76%
[DCF] Fair Price = unknown (Cash Flow -71.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 99.38 | Revenue CAGR: 59.60% | SUE: -0.79 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.41 | Chg30d=-31.50% | Revisions=+25% | Analysts=8
EPS current Year (2026-12-31): EPS=-2.49 | Chg30d=-46.13% | Revisions=+25% | GrowthEPS=+28.4% | GrowthRev=+52.6%
EPS next Year (2027-12-31): EPS=5.59 | Chg30d=-5.77% | Revisions=+25% | GrowthEPS=+324.7% | GrowthRev=+61.3%
[Analyst] Revisions Ratio: +50% (up=3, down=0)